SECURITIES AND EXCHANGE COMMISSION

FORM DEFA14A

Additional definitive proxy soliciting materials and Rule 14(a)(12) material

Filing Date: **1994-01-04**
SEC Accession No. 0000892569-94-000002

(HTML Version on secdatabase.com)

FILER

ICN PHARMACEUTICALS INC /DE/

CIK:**49601**| IRS No.: **952565381** | State of Incorp.:**DE** | Fiscal Year End: **1231**
Type: **DEFA14A** | Act: **34** | File No.: **001-05965** | Film No.: **94500308**
SIC: **2834** Pharmaceutical preparations

Mailing Address
3300 HYLAND AVENUE
COSTA MESA CA 92626

Business Address
3300 HYLAND AVE
COSTA MESA CA 92626
7145450113

Copyright © 2012 www.secdatabase.com. All Rights Reserved.
Please Consider the Environment Before Printing This Document

SCHEDULE 14A INFORMATION

Proxy Statement Pursuant to Section 14(a)
for the Securities Exchange Act of 1934

Filed by the Registrant /X/
Filed by a Party other than the Registrant / /

Check the appropriate box:

/ / Preliminary Proxy Statement
/ / Definitive Proxy Statement
/ / Definitive Additional Materials
/X/ Soliciting Material Pursuant 240.14a-11(c) or 240.14a-12

ICN PHARMACEUTICALS, INC.
(Name of Registrant as Specified in its Charter)

ICN PHARMACEUTICALS, INC.
(Name of Person(s) Filing Proxy Statement)

Payment of Filing Fee (Check the appropriate box):

/ / $125 per Exchange Act Rules 0-11(c)(1)(ii), 14a-6(i)(1), or 14a-7(i)(2).

/ / $500 per each party to the controversy pursuant to Exchange Act Rule 14a-6(i)(3).

/ / Fee computed on table below per Exchange Act Rules 14a-6(i)(4) and 0-11.

1) Title of each class of securities to which transaction applies:

2) Aggregate number of securities to which transaction applies:

3) Per unit price or other underlying value of transaction computed pursuant to Exchange Act Rule 0-11.*

4) Proposed maximum aggregate value of transaction:

*Set forth the amount on which the filing fee is calculated and state how it was determined.

/ / Check box if any part of the fee is offset as provided by Exchange Act Rule 0-11(a)(2) and identify the filing for which the offsetting fee was paid previously. Identify the previous filing by registration statement number of the Form or Schedule and the date of its filing.

Copyright © 2012 www.secdatabase.com. All Rights Reserved.
Please Consider the Environment Before Printing This Document

(1) Amount Previously Paid:
(2) Form, Schedule or Registration Statement No.:
(3) Filing Party:
(4) Date Filed:

FOR IMMEDIATE RELEASE

Contact: David Calef
Tel: (714) 545-0100 ext. 3048

SPI PHARMACEUTICALS WINS BID FOR STAFF IN LEADING HUNGARIAN DRUG MANUFACTURER

COSTA MESA, Calif., January 3, 1994 -- SPI Pharmaceuticals, Inc. of the United States, today announced that it reached an agreement with the Hungarian government to acquire a 30% ownership in Alkaloida, a leading pharmaceutical manufacturer in Hungary.

As part of its continuing program of worldwide expansion and as part of the tender offer, SPI said it intends to increase its percentage ownership in Alkaloida to controlling interest of over 50%. Actual closing of the transaction is subject to due diligence, auditing and normal terms and conditions relating to closing.

According to Adam Jerney, President of SPI Pharmaceuticals, "This partnership will strengthen the role of SPI Pharmaceuticals as a leader in marketing and manufacturing in Eastern Europe and around the world." According to Laszlo Dupcsak, General Manager of Alkaloida, "This is a major transaction for Hungary. We are pleased to have such a successful American pharmaceutical company for a partner."

Based in the city of Tiszavasvari, 100 miles northeast of the capital city of Budapest, near the Russian border, Alkaloida is a diversified pharmaceutical and chemical manufacturer established in 1927. Alkaloida is one of only 5 facilities worldwide for the production of medicinal morphine. Annual sales of Alkaloida are approximately $90 million, with almost two-thirds of the sales in foreign currency. The company makes and markets 60 products including morphine, cardiovasculars, non-steroid anti-rheumatics, antacids, anti-asthmatics and anti-malarials. It employs 2,100 people and sells products in Hungary and over 80 foreign countries, including the United States. The company recently completed construction on a state of the art pharmaceutical production facility which will add further to capacity.

SPI Pharmaceuticals (AMEX:SPI), headquartered in Costa Mesa, California, manufactures, markets and distributes more than 600 pharmaceutical products in over 60 countries throughout the world. SPI has facilities in the United States, Canada, Mexico, Western Europe, Eastern Europe and the former Soviet Union. SPI is 42% owned by ICN Pharmaceuticals, Inc. (NYSE:ICN).

Copyright © 2012 www.secdatabase.com. All Rights Reserved.
Please Consider the Environment Before Printing This Document

# # #

Copyright © 2012 www.secdatabase.com. All Rights Reserved.
Please Consider the Environment Before Printing This Document